Lupin receives FDA OK for generic Uloric
Febuxostat tablets are indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol.
Lupin has received approval from the Food and Drug Administration for Febuxostat tablets, 40 mg and 80 mg, which is the generic of Takeda’s Uloric. The product will be manufactured at Lupin’s Pithampur facility in India.
Febuxostat Tablets, 40 mg and 80 mg, are indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.
[Read more: Lupin receives FDA OK for generic Banzel]
Febuxostat Tablets(RLD Uloric) had a market value of $27 million, per IQVIA November 2023 data.